ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

nalfurafine

Also written as “IMM02-KORA”, “Remitch®” and “Nalfurafine hydrochloride(MT-9938) 2.5μg”.

Its studies are mostly in Pruritus · Dyskinesias · Kidney Failure, Chronic, led by 6 companies.

Drug pageTRK 820: every studyMany companies study it; this page follows only the 9 they lead. All 12 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Mar 12, 20089 company-led studies, 1 open or runningNext primary completion: Dec 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Toray Industriesits history only30 open or runningphase 2since Mar 12, 2008Mar 12, 2008none ahead
SK Chemicalsits history only20 open or runningphase 3since Nov 23, 2010Nov 23, 2010none ahead
3SBioits history only10 open or runningphase 3since Jan 26, 2021Jan 26, 2021none ahead
Acologixits history only10 open or runningphase 3since Nov 17, 2008Nov 17, 2008none ahead
Immunis11 open or runningphase 1since Oct 15, 2026Oct 15, 2026Dec 30, 2027phase 1 · NCT07905976
Lunan Pharmaceutical Groupits history only10 open or runningno phasesince Mar 12, 2026Mar 12, 2026none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Immunis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 15, 2026First study: phase 1 study in Dyskinesia, Drug-InducedFirst studyNCT07905976 · 15 planned

Ahead

  1. Dec 30, 2027Primary completion: phase 1 study in Dyskinesia, Drug-InducedNCT07905976

TargetBeta

OPRK1 →read by rule
“Kappa opioid receptor agonist”ChEMBL 37, by rule

Other programs on OPRK1

ProgramCompanyFurthest phaseStudies
Naltrexoneruleorexigen-therapeutics-incphase 442
NalbuphineruleTrevi Therapeuticsphase 421
nalmefeneruleH. Lundbeckphase 420
cebranopadolruleTris Pharmaphase 318
AticaprantruleJohnson & Johnsonphase 313
asimadolineruletioga-pharmaceuticalsphase 36
icalcaprantAbbViephase 26

Studies

The one study Immunis leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07905976Dyskinesia, Drug-Induced1Not yet recruitingDec 30, 202715

How it is read

Names in the registry

  • “IMM02-KORA”, 1 entry
  • “Remitch®”, 1 entry
  • “Nalfurafine hydrochloride(MT-9938) 2.5μg”, 1 entry
  • “Nalfurafine hydrochloride(MT-9938) 5μg”, 1 entry
  • “Nalfurafine hydrochloride(MT-9938) 10μg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.